Thyroid hormones are essential for maintaining a pregnancy and optimal fetal neurological development. Pregnancy places additional demands on the thyroid axis and around 5% of women who have their thyroid function checked during gestation will have borderline low thyroid function (subclinical hypothyroidism or isolated hypothyroxinemia) identified. These borderline low thyroid states are associated with adverse obstetric and offspring outcomes. Whilst it is well established that overt hypothyroidism requires treatment with levothyroxine, it is less clear whether there is any benefit of treating borderline low thyroid states. This review summarizes the potential indications for treatment of subclinical hypothyroidism and isolated hypothyroxinemia.

Indications for treatment of subclinical hypothyroidism and isolated hypothyroxinaemia in pregnancy / P.N. Taylor, I. Muller, M. Nana, I. Velasco, J.H. Lazarus. - In: BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL ENDOCRINOLOGY & METABOLISM. - ISSN 1521-690X. - 34:4(2020 Jul). [10.1016/j.beem.2020.101436]

Indications for treatment of subclinical hypothyroidism and isolated hypothyroxinaemia in pregnancy

I. Muller
Co-primo
;
2020-07

Abstract

Thyroid hormones are essential for maintaining a pregnancy and optimal fetal neurological development. Pregnancy places additional demands on the thyroid axis and around 5% of women who have their thyroid function checked during gestation will have borderline low thyroid function (subclinical hypothyroidism or isolated hypothyroxinemia) identified. These borderline low thyroid states are associated with adverse obstetric and offspring outcomes. Whilst it is well established that overt hypothyroidism requires treatment with levothyroxine, it is less clear whether there is any benefit of treating borderline low thyroid states. This review summarizes the potential indications for treatment of subclinical hypothyroidism and isolated hypothyroxinemia.
isolated hypothyroxinemia; levothyroxine; pregnancy; screening; subclinical hypothyroidism
Settore MED/13 - Endocrinologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
2020_Provisional_Taylor&Muller_Best Practice & Research Clinical Endocrinology & Metabolism.pdf

embargo fino al 01/07/2021

Descrizione: Articolo principale
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 966.95 kB
Formato Adobe PDF
966.95 kB Adobe PDF Visualizza/Apri
1-s2.0-S1521690X20300634-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 457.33 kB
Formato Adobe PDF
457.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/806769
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 5
social impact